Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update
Autonomix Medical reported 20–30-point gains in quality-of-life scores at three months in a subgroup analysis from its PoC 1 study for severe pancreatic cancer pain. Even Stage 4 patients saw durable symptom and function improvements after nerve ablation. AMIX shares nearly doubled intraday on heavy volume, ranking among Nasdaq’s top gainers. The company remains pre-revenue and highly volatile.
